BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Misses Expectations By $3.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04), FiscalAI reports. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The business had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. During the same period in the prior year, the firm posted $0.20 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• Strong commercial momentum: ORLADEYO net revenue was $148.3 million in Q1, with monthly new patient prescriptions slightly ahead of 2025 averages and early pediatric launch demand observed across all four pellet strengths.
• A manufacturing issue with ORLADEYO pediatric pellets will delay initial product fulfillment; the company says it does not expect the delay to change 2026 revenue guidance and will provide more timing details later this quarter.
• Development progress for navenibart is ahead of plan: ALPHA-ORBIT pivotal enrollment should complete by end of next month at ~145 patients, keeping a U.S. filing target by the end of 2027 and supporting a sizable injectable opportunity.
• Pipeline expansion: BCX17725 (KLK5 inhibitor) has started dosing in Part 4 of Phase I (up to 12 patients) with proof-of-concept data expected by year-end for Netherton syndrome.
• Mixed financial picture: GAAP was impacted by an in-process R&D charge of $698 million from the Astria asset acquisition, while non-GAAP results show strong operating profitability and pro forma liquidity of roughly $331 million after a $70 million upfront European license and a $400 million credit facility.

BioCryst Pharmaceuticals Stock Down 2.5%

BioCryst Pharmaceuticals stock traded down $0.23 during midday trading on Wednesday, reaching $8.81. The stock had a trading volume of 7,725,617 shares, compared to its average volume of 5,084,851. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 7.34 and a beta of 0.57. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The company has a fifty day moving average of $9.03 and a 200 day moving average of $7.80.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the transaction, the insider owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada grew its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in BioCryst Pharmaceuticals by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after buying an additional 8,517 shares during the period. Goldman Sachs Group Inc. grew its stake in BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after acquiring an additional 640,704 shares in the last quarter. Caxton Associates LLP bought a new position in BioCryst Pharmaceuticals in the 1st quarter worth about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after acquiring an additional 47,355 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q1 revenue beat and product sales growth—Q1 total revenue of $156.4M beat Street estimates, and ORLADEYO net revenue was $148.3M (+11% y/y; +21% y/y on a comparable basis excluding Europe), supporting the company’s top?line momentum. BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Adjusted/operational EPS metrics looked better in some outlets—Zacks notes an adjusted Q1 loss of $0.03/share versus a $0.06 estimate, a small beat that investors focused on as evidence of underlying profitability trends. BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains—Needham lowered its price target from $18 to $16 but kept a Buy rating, signaling continued analyst conviction in longer?term upside despite trimming expectations. Needham Lowers PT to $16 but Maintains Buy
• Neutral Sentiment: FY?2026 revenue guidance largely in line with consensus—the company issued revenue guidance of $635M–$660M (consensus ~$648.7M), a band that overlaps Street expectations and leaves the outlook somewhat neutral overall. BioCryst Q1 Earnings / Guidance Details
• Neutral Sentiment: Small equity grants to new hires—company disclosed inducement RSUs totaling 61,750 shares; dilution is modest but worth noting for longer?term capital structure. BioCryst Reports Inducement Grants
• Negative Sentiment: Large GAAP EPS miss and one?time items—some reports (MarketBeat/press materials) show a GAAP EPS loss of ($2.98) that missed consensus by a wide margin, creating headline risk and investor concern over non?operational charges or tax items driving the disparity between revenue strength and EPS. MarketBeat: Q1 Results and EPS Details
• Negative Sentiment: Conflicting headlines and investor uncertainty—differences between adjusted/operational metrics and GAAP results, plus follow?up disclosures (slides and call PDFs), are increasing short?term volatility as investors parse the causes. Q1 Slide Deck / Conference Materials

Wall Street Analyst Weigh In

BCRX has been the subject of a number of research reports. Evercore initiated coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price for the company. Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday. Royal Bank Of Canada lowered their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Finally, Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.10.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.